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Functional exploration of colorectal cancer
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The multigenic nature of human tumours presents a fundamental challenge for cancer drug
discovery. Here we use Drosophila to generate 32 multigenic models of colon cancer using
patient data from The Cancer Genome Atlas. These models recapitulate key features of
human cancer, often as emergent properties of multigenic combinations. Multigenic models
such as ras p53 pten apc exhibit emergent resistance to a panel of cancer-relevant drugs.
Exploring one drug in detail, we identify a mechanism of resistance for the PI3K pathway
inhibitor BEZ235. We use this data to identify a combinatorial therapy that circumvents this
resistance through a two-step process of emergent pathway dependence and sensitivity we
term ‘induced dependence’. This approach is effective in cultured human tumour cells,
xenografts and mouse models of colorectal cancer. These data demonstrate how multigenic
animal models that reference cancer genomes can provide an effective approach for
developing novel targeted therapies.
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C
ancer is a genetically complex and highly heterogeneous
disease with individual tumours typically carrying
mutations in dozens of genes. The revolution in genome
sequencing has provided unprecedented access to this genetic
complexity and diversity, and paved the way for precision
medicine approaches1–3. The basic premise of precision medicine
is to identify an alteration in an ‘actionable’ gene, one for which
an Food and Drug Administration (FDA)-approved drug or a
clinical trial is available4. However, such actionable alterations are
almost always found concurrent with other key cancer driver
mutations that can differ in individual patients and tumour types.
An understanding of how drug response changes in the context of
complex and diverse mutation combinations will be a key to the
success of precision medicine.
Genetic complexity and diversity of tumours present a major
challenge for cancer drug discovery5,6: oncology clinical trials
currently demonstrate among the lowest FDA approval rates of
all major diseases7. With important exceptions8–10, many drugs
identiﬁed by focusing on single genes or pathways struggle to
work in the clinic, even in patient populations that carry
alterations in the drugs’ targets. Examples include the MEK
inhibitors selumetinib and binimetinib in KRAS mutant
non-small cell lung cancer11 and NRAS- or BRAF-mutated
melanoma12, respectively, as well as phosphatidyl inositol
3-kinase (PI3K) pathway inhibitors for multiple PI3K mutant
tumour types13. Many of these clinical failures reﬂect the presence
of concurrent mutations in the patients’ genomes. Testing these
agents in the context of multiple cancer driver mutations will be
essential to identify genome proﬁles that can respond to these
drugs as single agents or, potentially, to identify useful drug
combinations. Recently reported methods for establishing and
drug screening three-dimensional culture models derived from
patients14,15 are promising in this regard. However, exploring
mechanisms of drug response and resistance, and identifying
drug combinations that overcome resistance require experimental
systems with sophisticated genetic tools. Mouse models built to
reﬂect commonly observed mutation combinations in human
tumours have begun to shed light on interactions between
individual mutations and pathways16,17. Organoid tumours
established by stepwise introduction of known colorectal cancer
driver mutations into human intestinal cells have also recently
been reported18,19. However, a systematic and comprehensive
exploration of human cancer genomes in vertebrate model
systems is a time-consuming and costly prospect, and poses a
signiﬁcant barrier to cancer research.
Drosophila with its arsenal of sophisticated genetic tools and
long history of modelling disease is an ideal model system for
functional exploration of human cancer genomes. Recent reports
demonstrating a high degree of conservation of drug activity also
make it a clinically relevant platform for drug screening20,21.
To this end, we developed a diverse panel of personalized
Drosophila models that reﬂect the multigenic and heterogeneous
nature of human tumours catalogued by the Cancer Genome
Atlas (TCGA)22. We focused on colon cancer, the second leading
cause of cancer-related death in the western world. Its high
mortality rate is largely due to the resistance of late-stage tumours
to targeted therapies. FDA approval rates in colon cancer are 5%
of drugs that enter clinical trials7 and effective therapeutics
remain an unmet need.
Highly conserved genes and pathways implicated in colon
cancer have been extensively studied in cell culture and
mouse models23,24. These pathways are highly conserved in the
Drosophila hindgut, the functional equivalent of the mammalian
colon25,26. When targeted to the adult Drosophila hindgut, our
models recapitulated key features of human cancer including
proliferation and disruption of the epithelial architecture, evasion
of apoptosis and senescence, epithelial–mesenchymal transition
(EMT), migration and dissemination to distant sites. Importantly,
this work identiﬁes intrinsic drug resistance as a key emergent
property of genetically complex tumours. To demonstrate the
practical utility of this approach, we identify a mechanism of
resistance for the PI3K/mammalian target of rapamycin (mTOR)
inhibitor BEZ235. We also identify a two-step therapy that
overcomes this resistance by a novel mechanism that is also
effective in cultured human colorectal cancer cell lines, xenografts
and a genetic mouse model of colorectal cancer. Our work
demonstrates that Drosophila can be a useful platform for rapid
and large-scale functional exploration of human cancer genomes.
Results
Genomic analysis of colon tumours from TCGA. Genomic
studies have identiﬁed B25 genes recurrently mutated in colon
tumours, leading to misregulation of ﬁve distinct signalling
pathways22,27–29: Wnt, receptor tyrosine kinase (RTK)/Ras, p53,
transforming growth factor-b and PI3K (Supplementary Table 1
and Supplementary Data 1). We determined the mutation status
of these 25 genes within 212 TCGA colon tumours, for which
there is sequencing and copy number alteration data available22,
and grouped the patients by pathway alteration status (Fig. 1a,b
and Supplementary Data 2). For oncogenes, we focused only on
ampliﬁcation events and known activating mutations, excluding
from our analysis nonsense mutations and missense mutations of
unknown functional signiﬁcance. For tumour suppressors, all
nonsense, missense mutations and deletion events were included
(Supplementary Data 1).
Consistent with previous analyses, the most frequently
observed misregulation event was activation of the Wnt pathway
(180 patients, 85% of the patients in the data set) followed
by RTK/Ras (135 patients, 64%), p53 (131 patients, 62%),
transforming growth factor-b (74 patients, 35%) and PI3K
(53 patients, 25%; Fig. 1b,c). Interestingly, despite the high
degree of misregulation of each pathway in the population, only a
small fraction of patients had mutations exclusively in a single
pathway (22 patients, 10%; Fig. 1c). Most patients have more than
one well-established cancer driver mutation. Indeed, we found
that 30% of the patient population carried mutations in two
pathways, 40% in three pathways, 15% in four and 5% in all ﬁve
(Fig. 1d). Overall, the most frequently observed event was
co-misregulation of RTK/Ras, p53 and Wnt pathways.
This genetic complexity may prove signiﬁcant, as most cancer
drug discovery and precision medicine approaches focus on
individual signalling pathways and actionable genes. If most
actionable mutations in the patient population occur in the
context of other cancer driver mutations, it raises a question: can
tumours be best addressed as the sum of their mutations or do
emergent properties alter drug response in unpredictable ways?
A better understanding of drug response in a diverse set of
genetically complex cancer models could inform precision
medicine approaches.
Multigenic models of colorectal tumours. To model speciﬁc
human tumours in Drosophila, we selected a transgenic
Drosophila line corresponding to the most frequently mutated
gene in each pathway (Fig. 1a) to represent deregulation of that
pathway. We used RNA interference (RNAi) lines to knock
down tumour suppressors and a rasG12V transgene to model the
oncogenic isoform KRASG12V. We then generated the appropriate
combination of these ﬁve transgenes to represent the pathway
alteration status observed in each patient (Supplementary Table 2
and Supplementary Data 2). Our collection contains 32
multigenic models representing 212 human tumours; the exact
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mutation complement, pathway alteration status and corre-
sponding Drosophila model for each human tumour is shown in
Supplementary Table 2 and Supplementary Data 2.
Hallmarks of cancer include hyperproliferation, disruption
of the normal tissue architecture, evasion of apoptosis and
oncogene-induced senescence, migration and metastasis30.
To determine which aspects of tumorigenesis our multigenic
combinations recapitulated we targeted the appropriate trans-
genes speciﬁcally to the adult Drosophila hindgut epithelium
(Fig. 2a), the functional equivalent of the mammalian colon25,26.
The adult hindgut is a single-layer epithelium divided into three
main sections along its anterior–posterior axis25,26 (Fig. 2b):
(i) the pylorus is the anterior-most region of the hindgut that
controls the passage of gut contents from the midgut to the
hindgut, (ii) the ileum contains the differentiated enterocytes and
(iii) the rectum sits most posteriorly.
The temperature-sensitive Gal4/Gal80ts system and the
hindgut-speciﬁc byn promoter were used to control the
timing and location of transgene expression31,32. Multigenic
combinations were targeted to the adult hindgut along with
Dicer2 and green ﬂuorescent protein (GFP). Using one of the
quadruple combinations rasG12V p53Ri ptenRi apcRi, we showed
that expression levels were unaffected by the number of
transgenes and that byn-gal4 levels were sufﬁcient to efﬁciently
direct transgene expression and knock down (Supplementary
Fig. 1).
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Figure 1 | Multigenic Drosophila cancer models based on TCGA colorectal cancer genomes. (a) Population frequencies and distribution of recurrently
mutated genes within the TCGA colorectal tumour data set. Each rectangular bar indicates a patient in the population. Drosophila transgenic lines
selected to model alteration of each pathway are indicated. (b) Mutation proﬁles of individual tumours with respect to the ﬁve deregulated pathways.
Purple bars indicate patients carrying an alteration in a recurrently mutated gene within a pathway; grey bars indicate tumours with no alterations in that
pathway. (c) Frequency of alteration of the ﬁve pathways in the patient population (left: overall frequency; right: frequency in the absence of additional
alterations). (d) Frequency of patients that show alterations in one, two, three, four and ﬁve pathways.
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One week after induction of the four- and ﬁve-hit models, two
phenotypes became apparent: regions of multilayered epithelia
formed as bulges at discrete points along the hindgut (Fig. 2b–g)
and the pylorus was expanded (Fig. 2f,g), likely due to
hyperproliferation. We examined our transgenic lines in various
combinations to identify the primary drivers of these two
phenotypes. Expansion of the pylorus was observed in response
to the quintuple and all quadruples that carried rasG12V. Notably,
multilayering was observed only in animals that contained
rasG12V and apcRi together (see below). This indicates multi-
layering is an emergent property of oncogenic ras plus reduced
apc activity.
Transformed cells displayed migratory behaviour. We also
observed a strong EMT phenotype. In hindguts of four- and
ﬁve-hit models—with the exception of p53Ri ptenRi dSmad4Ri
apcRi, which notably lacked rasG12V—numerous cells lost their
characteristic epithelial shape to assume a more mesenchymal
appearance. Cells extended processes towards the basement
membrane and the surrounding muscle layer (Fig. 2j–o). Further,
many epithelial cells left the hindgut epithelium to migrate on top
of the surrounding muscle layer (Fig. 2p,q). Although rarely
preserved during ﬁxation, these migrating cells were commonly
observed to enwrap tracheal branches, a tubular network that
provides oxygen to Drosophila tissues (Fig. 2p, inset).
Src is a key regulator of EMT and cell migration, and its
activity is commonly upregulated in advanced tumour types33.
We assessed Src phosphorylation in rasG12V p53Ri ptenRi apcRi
hindguts, which displayed a strong EMT-like phenotype. Cells
displayed elevated levels of phosphorylated Src that included
strong membrane localization (Fig. 2r,s). Matrix metalloproteases
(MMPs) are secreted by transformed cells to degrade the
basement membrane during metastasis34; transformed ﬂy
hindguts exhibited strong but non-uniform MMP1 expression
throughout the epithelium (Fig. 3a–d). Presumably, as a result,
the basement membrane component Laminin was disrupted
particularly in the region between the epithelium and the
surrounding muscle, indicating that the integrity of the
basement membrane was compromised (Fig. 3e–l). These data
indicate that our colorectal cancer models recapitulate key steps
in the epithelium’s progression towards transformation.
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Figure 2 | Targeting quadruple combinations to the adult hindgut. (a) The adult Drosophila digestive track. Hindgut cells are visualized with byn4GFP;
nuclei are in red. (b–i) Control (byn4GFP,dcr2) and rasG12V p53Ri ptenRi apcRi hindguts 7 and 21 days after induction. Asterisks in c and e indicate regions of
multilayering. Longitudinal optical sections (f,g) and pylorus regions (h,i) are shown. (j–o) Control (j) and rasG12V p53RiptenRi apcRi (k–o) ilea; arrows
indicate migrating cells. (l) Close-up view view of k. (m–o) Apical-to-basal confocal sections of a migrating cell (asterisk). (p,q) Surface views of rasG12V
p53Ri smad4Ri apcRi hindguts with cells migrating on top of the muscle layer. (p) Inset: laminin (grey) and GFP channels only to highlight trachea (arrows).
(r,s) Phospho-Src staining of control and rasG12V p53Ri ptenRi apcRi hindguts.cr, crop; h, hindgut; i, ileum; m, midgut; mp, malphigian tubules; p, pylorus;
r, rectum; t, trachea. Scale bars, 250mm (a–e) and 25mm (f–s).
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Transformed cells migrated to distant sites. As GFP-positive
hindgut cells transformed, many migrated to distant sites. Five-
and four-hit models that contained rasG12V displayed numerous
GFP-positive foci throughout their bodies including the head,
legs, fat body, ovaries, below the epidermis of the abdomen and
within the abdominal cavity; many of these foci were multicellular
(Fig. 3m–s). The disseminated foci were attached to the
abdominal body wall or other organs through the tracheal system
(Fig. 3m, inset), which presumably provided tracks for migrating
cells to reach distant sites as well as a source of oxygen. These
strong dissemination and EMT phenotypes recapitulate key early
aspects of metastasis.
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Figure 3 | Dissemination phenotypes induced by four- and ﬁve-hit models. (a–d) Mmp1 staining of control and rasG12V p53Ri ptenRi apcRi hindguts.
(b,d) Mmp1 channel only. (e–l) Cross-section views of control and rasG12V p53Ri ptenRi apcRi hindguts. (f,h,j,l) Laminin channel only; arrows indicate reduced/
absent laminin staining. (m–s) Examples of dissemination phenotype. Arrows indicate GFP-positive foci inside the abdominal cavity (m), underneath the
abdomen epidermis (n), ovaries (o), head (p) and legs (q,r) (f, fat body, n, nephrocyte; t, trachea). (m) Inset: close-up view showing close association of GFP foci
with tracheal branches. (s) Live confocal image of a multicellular GFP cluster inside the abdominal cavity. Nuclei are visualized by a nuclear dsRed transgene
(nls-dsRed). (t) Quantiﬁcation of dissemination into the abdominal cavity. Each animal is dissected and assigned into one of the following categories based on
the number of disseminated foci inside the abdominal cavity: none, no dissemination; weak, 1–3 GFP-positive foci inside the abdominal cavity; moderate, 4–10
GFP-positive foci; strong, 410 GFP-positive foci (n¼ 2 replicates, 20–30 ﬂies per replicate; error bars: s.e.m.). Scale bars, 25mm.
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We quantiﬁed dissemination into the abdomen by categorizing
animals based on the number of GFP-positive foci that collected
into their abdominal cavity over time (Fig. 3t). A strong
dissemination phenotype was evident with all combinations that
contained rasG12V starting at 7 days after induction, with rasG12V
dSmad4Ri ptenRi apcRi displaying the strongest expressivity. We
were not able to monitor dissemination beyond 1 week in this
quadruple and in the quintuple model due to signiﬁcant animal
lethality (Fig. 3t). Time-course analysis of dissemination revealed
that this phenotype did not get stronger over time in some
combinations (Fig. 3t), suggesting that animals with the strongest
phenotypes were progressively removed from the population. Of
note, we only observed a very mild dissemination phenotype with
p53Ri ptenRi dSmad4Ri apcRi (Fig. 3t), indicating that rasG12V is
required for signiﬁcant dissemination.
Our analysis of ﬁve- and four-hit models indicated that our
models capture key features of human tumours. We next
explored how individual transgenes in our models interact to
give rise to these tumour phenotypes. For this analysis, we
focused on one of the four-hit combination lines, rasG12V p53Ri
ptenRi apcRi.
Complex gene interactions regulate transformation and migration.
The Drosophila hindgut epithelium is normally quiescent,
although stem cells are stimulated to proliferate in response
to tissue damage or rasG12V (Fig. 4a,b,d)26,35. These
5-bromodeoxyuridine (BrDU)-positive cells are the progeny of
normally quiescent hindgut stem cells that are ‘pushed’ into
the pylorus region over time35. We observed large numbers of
BrDU-positive cells in the pylorus of rasG12V p53Ri ptenRi apcRi
hindguts labelled for 7 days, but not in controls (Fig. 4b,c). This
suggests that expansion of the pylorus region in response to the
quadruple combinations is also due to proliferation of normally
quiescent stem cells.
rasG12V was necessary for this proliferation phenotype35
(Fig. 4d): the remaining transgenes alone or in combination
had no measurable effect on proliferation. Addition of ptenRi or
apcRi strongly synergized with rasG12V to induce proliferation
and rasG12V ptenRi apcRi exhibited the strongest proliferative
phenotype (Supplementary Fig. 2a–d). Addition of p53Ri
consistently reduced proliferation (Fig. 4c–e and Supplementary
Fig, 2a–d); in mammals, a similar reduction has been attributed to
the accumulation of persistent DNA damage over time36,37.
Alternatively, reduced proliferation may reﬂect a role for p53 in
sensing progressive damage within neighbouring transformed
hindgut tissue.
Analysis of double and triple combinations demonstrated
that multilayering required combining rasG12V and apcRi: both
rasG12V p53Ri ptenRi smad4Ri and p53Ri ptenRi dSmad4Ri apcRi
lacked a multilayering phenotype (Fig. 4f–j), highlighting the
importance of reduced apc.
We also observed complex interactions with regard to
dissemination of transformed cells. rasG12V has been reported
to induce loss of cell polarity and basal delamination in a
mammalian two-dimensional monolayer cell culture model38 and
we previously observed that expressing rasG12V alone led to a
strong hindgut dissemination phenotype35. We found that this
rasG12V-induced dissemination was signiﬁcantly enhanced in the
quadruple rasG12V p53RiptenRi apcRi. Expressing p53Ri, ptenRi,
dSmad4Ri or apcRi—alone or in combination—displayed low
levels of dissemination (Figs 3t and 4k, and Supplementary
Fig. 2k). Curiously, pairing single transgenes with rasG12V
displayed stronger dissemination phenotypes than triple
combinations or even rasG12V p53Ri ptenRi apcRi (Fig. 4k). We
therefore explored the possibility that targeting all four pathways
provides enhancements to tumour progression that outweigh
reduced dissemination.
Advantages conferred to tumours by multigenic combinations.
Migrating rasG12V cells—and most double combinations—were
typically small and extended short processes (Fig. 4l). Migrating
cells in triple and quadruple combinations were signiﬁcantly
larger and extended longer processes (Fig. 4l). These phenotypes
suggest that triple and quadruple combinations led to a more
complete transformation process, yielding apparently more
robust migrating cells.
Apoptosis is an important cellular defense against cancer and
tumour cells acquire methods to evade it39. Control hindguts
displayed no detectable caspase activation as assessed by cleavage
of the initiator caspase Dronc (Fig. 5a). High levels of caspase
activity were observed with rasG12V alone, weaker levels were
observed with ptenRi and none with p53Ri or apcRi (Fig. 5b
and Supplementary Fig. 2). In contrast to rasG12V alone, no
caspase activation was detected in rasG12V p53Ri ptenRi apcRi
hindguts (Fig. 5c), indicating that one consequence of reducing
tumour suppressor activity is to block rasG12V-dependent caspase
cleavage.
Caspase activation was reduced in rasG12V ptenRi hindguts and
undetectable in rasG12V p53Ri hindguts, whereas apcRi had no
effect, indicating that intact Pten and P53 activities are required
to initiate or sustain apoptotic signalling in the context of rasG12V
(Fig. 5d and Supplementary Fig. 2). Further complexity emerged
within triple combinations: p53Ri failed to suppress caspase
cleavage induced by rasG12V apcRi but did so when paired
with ptenRi (Supplementary Fig. 2). We conclude that, in the
transformation process, higher pathway complexity favours a
block in apoptosis.
We observed that a subset of hindgut cells lost GFP
ﬂuorescence over time, most notably those bearing rasG12V or
rasG12V ptenRi, or, to a lesser extent, ptenRi alone (for example,
Supplementary Fig. 2). These same GFP-negative cells were
positive for the senescence marker SA-b-gal (Supplementary
Fig. 2 and Fig. 3e–h), indicating emergence of at least some
aspects of cellular senescence, a key cellular defense against
malignant progression40,41. Interestingly, in hindguts carrying
rasG12V, the addition of either p53Ri or apcRi was sufﬁcient to
reduce the number of cells positive for SA-b-gal activity (Fig. 5h
and Supplementary Fig. 2). In the context of rasG12V ptenRi,
however, simultaneously reducing both p53 and apc was required
to prevent SA-b-gal activity (Fig. 5g and Supplementary Fig. 2).
Again, greater complexity was required to promote tumour
progression and evade the tissue’s anti-tumour safeguards. That
is, complexity favours a block in both caspase cleavage and a
senescence-like phenotype, although the genetic details leading to
these events are different.
Together, these results reveal emergent properties by which loci
interact in complex ways to promote tumorigenesis (Fig. 5i,j).
They also highlight the ability of Drosophila to identify these
interactions within the context of the whole gut.
Genetically complex models are resistant to targeted agents.
The success rate of colorectal cancer clinical trials has remained
low as patients—in particular those with KRAS mutations—have
shown resistance to a broad palate of targeted therapies. Given
the genetically complex and diverse nature of colon tumours,
we explored whether increasing genetic complexity inﬂuences
a tumour model’s response to drugs. We used dissemination
into the abdominal cavity as a quantitative readout to measure
compound efﬁcacy; this provides a complex downstream
phenotype that measures the ability of transformed cells to
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migrate and survive at distant sites. We selected 16 compounds
that target key cancer relevant pathways and cellular processes
(Supplementary Fig. 3c); many of these compounds are currently
in clinical trials, including for colorectal cancer42,43. Final
compound concentrations in the media ranged from 0.1 mM to
1mM; based on adult feeding rates, we estimate the amount of
ingested compounds to be in the range of 10–200 ng per day per
animal (Supplementary Fig. 3c). After 7 days of compound
feeding, animals were dissected and number of disseminated foci
in the abdominal cavity counted as described (see Fig. 3t and
legend). Of note, control, rasG12V and rasG12V p53Ri ptenRi apcRi
all consumed similar food volumes (Supplementary Fig. 3d).
In rasG12V animals, 12/16 compounds signiﬁcantly suppressed
dissemination (Fig. 6a,b and Supplementary Fig. 3a). In contrast,
the four-hit model rasG12V p53Ri ptenRi apcRi was resistant to all
tested compounds: 0/16 compounds demonstrated a statistically
signiﬁcant effect on dissemination (Fig. 6a,b and Supplementary
Fig. 3b). We did not observe signiﬁcant whole-animal toxicity,
except for the proteasome inhibitor bortezomib (velcade), which
only showed efﬁcacy at doses that otherwise killed more than 70%
of the animals (Supplementary Fig. 4). The histone deacetylase
inhibitor panobinostat was effective against rasG12V but was
similarly toxic at doses that otherwise rescued rasG12V p53Ri
ptenRi apcRi (Supplementary Fig. 4). Together, our data indicate
that drug resistance is an important emergent property of
multigenic combinations: activating multiple cancer pathways can
lead to resistance to a wide range of anti-cancer agents. We next
explored a drug:tumour interaction in detail with the goal of
identifying and addressing the mechanism of resistance.
Drug resistance in multigenic combinations. Despite the
importance of PI3K pathway activity for tumour progression,
inhibitors have failed to show efﬁcacy in a broad range of
tumours44. An example is BEZ235, the ﬁrst PI3K/mTOR
inhibitor to enter clinical trials45. Mirroring clinical trial results
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in patients with mutations that directly activate PI3K signalling,
BEZ235 failed to reduce dissemination in rasG12V p53Ri ptenRi
apcRi animals despite their reduced phosphatase and tensin
homologue (PTEN) activity. Removing ptenRi from the quadruple
combination (rasG12V p53Ri apcRi) rendered the animals sensitive
to BEZ235; conversely, pairing rasG12V with ptenRi was sufﬁcient
to direct resistance (Fig. 6c). That is, resistance to the PI3K/
mTOR inhibitor BEZ235 is an emergent property of pairing
rasG12V with reduced pten activity. Our results suggest that
tumours with activation of both pathways may respond poorly to
PI3K pathway inhibitors; recent data from preclinical models and
human clinical trials also suggest BEZ235 resistance by tumours
that pair activation of Ras and PI3K pathways46–50.
PI3K activation leads to phosphorylation of AKT (p-AKT),
which in turn has multiple targets such as Tor Complex 1
(mTORC1) that regulate cell survival, growth and
metabolism51,52. Based on western analysis, rasG12V p53Ri
ptenRi apcRi and rasG12V ptenRi both had very high levels of
p-AKT. However, mTORC1 activity—as assessed by 4EBP
phosphorylation, a direct mTORC1 target—was low (Fig. 6d,e).
This unique state of PI3K pathway output (high p-AKT/low
mTORC1) was an emergent property of rasG12V plus ptenRi
(Fig. 6d,e) and correlated with resistance to PI3K pathway
inhibitors as single agents (Fig. 6c–e).
The high p-AKT/low mTORC1 bifurcation emerged over time.
Initially, rasG12V p53Ri ptenRi apcRi hindguts displayed activation
of both AKT and mTORC1 (Fig. 6e) but, over time, p-AKT levels
steadily increased and mTORC1 activity decreased until cells
reached a steady state with (i) high levels of p-AKT but (ii) low
levels of p-4EBP (Fig. 6e). Previous work in mammalian cells and
in Drosophila identiﬁed a similar high p-AKT/low mTORC1 state
induced by FoxO to maintain energy homeostasis in response to
physiological stress53,54. Furthermore, activating mutations in
PI3K were associated with low TORC1 activity in estrogen
receptor (ER)-positive breast tumour samples, although the status
of Ras/mitogen-activated protein kinase activation was not
reported55.
This bifurcation was not observed in animals containing
rasG12V or ptenRi alone. Although both AKT and mTORC1 were
activated early on in response to rasG12V or ptenRi as single
transgenes, by day 7 (i) p-AKT and p-4EBP levels had returned to
baseline (Fig. 6d,e) and (ii) the total levels of AKT protein were
very low (Supplementary Fig. 5). This altered proﬁle likely reﬂects
a feedback inhibitory loop that controls AKT protein stability in
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response to chronic PI3K pathway activation56. In our
experiments, this feedback loop was disrupted speciﬁcally when
rasG12V and ptenRi were present together. We conclude that
sensitivity to PI3K pathway inhibitors requires high mTORC1
activity; p-4EBP levels serve as a marker for this sensitivity.
Co-activation of Ras and PI3K pathways blocks mTORC1
elevation and therefore sensitivity to BEZ235 (Fig. 6h).
Consistent with this view, we observed a reduction in p-4EBP
levels in response to BEZ235 and rapamycin in rasG12V hindguts,
demonstrating that these compounds targeted the PI3K pathway
as expected (Fig. 6f). In contrast, p-4EBP levels were unchanged
in rasG12V p53Ri ptenRi apcRi hindguts. That is, PI3K pathway
inhibitors reduced mTORC1 activity in rasG12V but not in
rasG12V p53Ri ptenRi apcRi. This resistance likely reﬂects the
already very low baseline levels of p-4EBP in rasG12V p53Ri ptenRi
apcRi hindguts (Fig. 6f). Perhaps PI3K inhibitors lose their
efﬁcacy, as they cannot reduce the mTORC1 activity lower than
the already low baseline levels.
Increasing mTORC1 activity conferred drug sensitivity.
If resistance of rasG12V p53Ri ptenRi apcRi animals to PI3K
pathway inhibition is due to low mTORC1 activity in trans-
formed cells, activating mTORC1 in these animals should render
them sensitive to PI3K pathway inhibitors. We genetically
increased mTORC1 activity by reducing activity of two negative
regulators of mTORC1, tsc1 or tsc2. The result was a modest but
statistically signiﬁcant response to BEZ235 in rasG12V p53Ri ptenRi
apcRi animals (Fig. 6g).
Genetic manipulation experiments such as tsc knockdown
typically generate strong long-term activation—a functional
‘switch’—and lack temporal control. This is evident by the strong
enhancement of dissemination by tsc knockdown and the modest
response to BEZ235. To achieve a more transient activation
of mTORC1 that does not enhance rasG12V p53Ri ptenRi apcRi-
induced dissemination, we used the AKT-activating compound
SC79 (ref. 57). We found that SC79 also activated the Drosophila
PI3K pathway in a dose-dependent manner (Fig. 7a). We then
tested whether pharmacological activation of the PI3K pathway
would confer sensitivity to subsequent treatment with PI3K
pathway inhibitors in a two-step ‘therapy’. Pretreatment of
rasG12V p53Ri ptenRi apcRi animals with SC79 followed by BEZ235
signiﬁcantly suppressed dissemination, speciﬁcally at doses of
SC79 that activated mTORC1 (Fig. 7b). Importantly, the efﬁcacy
of SC79/BEZ235 treatment was lost when the order of the two
drugs was reversed (Fig. 7b); this rules out additive effects and
emphasizes the order of drug treatment as an essential aspect of
the mechanism of action of the two-step therapy. Using the most
effective dose of SC79, we found that a 1-day/2-day alternating
treatment schedule was also effective, whereas either drug alone
did not have any statistically signiﬁcant effect on dissemination
(Fig. 7c). These ﬁndings support a two-step model of
‘induced dependence’ (Figs 6h and 8f): SC79 treatment induces
dependence on mTORC1 by increasing its activity; this in turn
confers sensitivity to dual PI3K/mTOR inhibitors.
These data demonstrate that a drug can be used to promote
‘induced dependence’ on its target pathway, creating new drug
sensitivities within a tumour in a rational and controlled manner.
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This can be useful to address the complex networks that emerge
due to interactions between cancer genes. Finally, with regard to
tumours with PI3K and Ras pathway mutations, mTORC1
activity is a determinant of sensitivity to PI3K/mTOR inhibitors.
A clinically relevant two-step therapy to overcome resistance.
We had previously noted that the proteosome inhibitor
bortezomib directed upregulation of mTORC1 activity. We next
tested whether bortezomib can be combined with BEZ235 as a
more clinically relevant two-step therapy. Bortezomib induced
mTORC1 activity in rasG12V p53Ri ptenRi apcRi animals at
1–10 mM dose range in the food; the strongest activation was
observed at 5 mM (Fig. 8a). As with SC79, sequential treatment of
rasG12V p53Ri ptenRi apcRi animals with bortezomib followed by
BEZ235 was effective in suppressing dissemination (Fig. 8b).
Reversing the order of the drugs again rendered the two-step
therapy ineffective (Fig. 8b). Again, as with SC79, a 1-day/2-day
alternating treatment schedule of bortezomib and BEZ235 was
effective, whereas either drug alone had no effect (Fig. 8c).
Although SC79 directly and speciﬁcally activates the PI3K
pathway by binding AKT, bortezomib is a proteosome inhibitor
with pleiotropic effects. Our ﬁnding that reversing the order of
drugs in bortezomib/BEZ235 treatment is a speciﬁc prediction of
the mechanism of the action of our two-step therapy and rules
out any additive effects of these two drugs. To further conﬁrm
that the ability of bortezomib to activate mTORC1 is essential for
the efﬁcacy of the two-step therapy, we genetically reduced levels
of Raptor—a component of the mTORC1 complex—in rasG12V
p53Ri ptenRi apcRihindguts. Bortezomib-induced upregulation of
mTORC1 activity was blocked by knocking down raptor (Fig. 8d),
rendering bortezomib/BEZ235 two-step therapy ineffective
b
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(Fig. 8e). These ﬁndings demonstrate that the efﬁcacy of the
bortezomib/BEZ235 two-step therapy is dependent on the ability
of bortezomib to increase mTORC1 activity.
Validation in mammalian models of colorectal cancer. Finally,
we examined whether our ﬁndings were relevant to human
tumour cells. The human colorectal cancer cell line DLD-1
contains mutations in Ras, p53, adenomatous polyposis coli
(APC) and an activating mutation in the PI3K pathway compo-
nent PIK3CA, a combination that leads to an overall molecular
state similar to our Drosophila rasG12V p53Ri ptenRi apcRi model.
As our model predicted, DLD-1 proved more resistant to BEZ235
than the derivative line DLD-1-WT, in which normal PIK3CA
function is restored58 (Fig. 9a). Also consistent with our ﬂy
observations, bortezomib activated the PI3K pathway in these
cells at doses and durations that did not affect survival but that
rendered DLD-1 cells sensitive to BEZ235 treatment (Fig. 9b–d
and Supplementary Fig. 6a,b). We conﬁrmed these observations
with the HCT116 cell line—co-activated for the Ras/mitogen-
activated protein kinase and PI3K pathways—and its derivative
HCT116-WT58 (Supplementary Fig. 6c–f).
We next tested the combination therapy in DLD-1 xenografts.
Bortezomib can inhibit or activate the PI3K pathway depending
on the cell type, dose and duration of treatment59–61.
Initial dosing experiments with bortezomib alone demonstrated
PI3K pathway activation at a wide range of doses
(0.5–0.01mg kg 1). Sequential treatment of xenograft tumours
with bortezomib (0.01mg kg 1) followed by BEZ235 was
signiﬁcantly more effective at reducing tumour growth rates
than BEZ235 alone (Fig. 9e,f), whereas bortezomib alone had no
effect on tumour growth (Supplementary Fig. 7). Despite
signiﬁcant reduction of tumour growth rates we did not
observe tumour regression, perhaps due to the more aggressive
growth rates of xenograft tumours derived from human cancer
lines compared with primary human tumours6.
Focusing on a genetically engineered mouse model, cultured
spheres derived from APC/KRAS/PTEN intestinal tumours were
largely insensitive to BEZ235 as a single agent; however, they
responded to sequential treatment with bortezomib followed by
BEZ235 (Fig. 10a). Again, reversing the order of the treatment
eliminated efﬁcacy of the two-step therapy (Fig. 10a).
Furthermore, and consistent with our ﬁndings in Drosophila,
bortezomib could be replaced by SC79 in this assay as well;
reversing the order of drug administration also eliminated
efﬁcacy (Fig. 10b).
Allograft tumours derived from APC/KRAS/PTEN spheres
were also sensitive to sequential treatment: strikingly, three of ﬁve
allograft tumours showed regression in response to 0.01mg kg 1
bortezomib followed by BEZ235 (Fig. 10c). Although BEZ235 or
bortezomib alone also reduced tumour size in some animals, no
tumour regression was achieved (Fig. 10c). We conclude that
induced dependence can be leveraged in vivo to reduce tumour
progression.
Discussion
As more tumours are being sequenced, there is an increasing need
for model systems that provide functional validation of this
sequence data at a scale and speed that can match genome-wide
tumour proﬁling studies. We demonstrate how Drosophila can be
used to address an important area of unmet need by modelling a
major cancer type and exploring mechanisms of drug response
and resistance in the context of genetically complex models. Our
study is the ﬁrst to build a set of genetically complex models
directly based on individual tumour genome proﬁles. To our
knowledge, these models represent the most extensive set of
personalized transgenic cancer models to date.
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Our multigenic models capture key features of human colon
tumours many of which showed complex multigenic regulation
(Fig. 5i,j). The signiﬁcant variation observed between speciﬁc
transgene combinations emphasizes the potential differences
between tumours from different patients and suggests the
importance of personalized therapies. For example, we show that
resistance to targeted therapies is a key emergent feature of
genetically complex tumours. If drug response is highly
dependent on genomic context with different mechanisms of
resistance depending on the identity of concurrent driver
mutations, more sophisticated patient stratiﬁcation approaches
based on whole-genome proﬁles rather than individual genes will
be key to the success of precision medicine approaches. Such a
transition from actionable genes to actionable genomes can only
be accomplished by using more diverse and personalized
preclinical models for cancer drug discovery. Such models can
also lead to the discovery of a different class of anti-cancer agents
that target novel emergent vulnerabilities that are revealed as a
result of complex interactions between concurrent mutations.
Exploring the mechanisms of drug response and resistance,
we found that resistance to PI3K pathway inhibitors such as
BEZ235 was an emergent property of Ras activation plus Pten
loss. These results match recent data from multiple preclinical
models and from human clinical trials as well46,47, demonstrating
that Drosophila can be a useful platform to identify mutation
proﬁles associated with drug resistance in cancer patients and
identify underlying molecular mechanisms. PI3K pathway is one
of the most investigated pathways for cancer therapy, with a large
number of therapeutic agents under clinical development. Despite
the importance of this pathway in oncogenic transformation,
PI3K pathway inhibitors have demonstrated modest clinical
activity as single agents44. Our demonstration that the resistance
state of rasG12V ptenRi cells can be altered by genetically
increasing baseline levels of mTORC1 activity opens up new
avenues for PI3K pathway inhibitors in the clinic as part of drug
combinations that exploit this mechanism of resistance.
Furthermore, the two-step therapy was also effective in cell
lines that carry activating mutations in PIK3CA, rather than
PTEN loss. Despite the well-established differences in PTEN loss
and PIK3CA activation, these mutations behave similarly in their
response to the two-step therapy, suggesting that tumours
carrying either PTEN loss or oncogenic mutations in PIK3CA
could beneﬁt from the two-step therapy. Our demonstration
that bortezomib can alter the resistance state of rasG12V ptenRi
a b
Vi
ab
ilit
y
log [BEZ235] (nM)
DLD-1:  RAS P53 PIK3CA APC 
DLD-1 WT:  RAS P53 APC Bortezomib (nM)
Hours
p4
EB
P 
fo
ld
 c
ha
ng
e
Bortezomib (nM): 12 h
D
M
SO
0.1 0.5 1 202.5 5 10
15 kDa
42 kDa
50
0.1 1 10010
9 14 17 21 24 28 31
0.0
1.0
4.0
140
120
100
80
60
40
20
0
3.5
3.0
2.5
2.0
1.5
Time point:12 h
p4
EB
P 
fo
ld
 c
ha
ng
e
log [Bortezomib] (nM)
c d
e f
Bortezomib (nM)
Vi
ab
ilit
y
1 day bortezomib + 2 days BEZ235
0
500
1,000
1,500
2,000
%
 C
ha
ng
e
 in
 
tu
m
ou
r 
vo
lum
e
Bortezomib
BEZ235
–
+– + + +
0.25 0.1 0.01–
*
*
%
 C
ha
ng
e 
in
 tu
m
ou
r v
o
lu
m
e
Days
Vehicle
BEZ235
Bortezomib (0.25 mg kg–1)/BEZ235
Bortezomib (0.1 mg kg–1)/BEZ235
Bortezomib (0.01 mg kg–1)/BEZ235
p4EBP
Actin
160
3.5
3
2.5
2
1.5
1
0.5
0
140
120
100
80
60
40
20
0
1 10 100 1 4 12 18 24
0.1
0.5
1
2.5
5
10
20
50
–
0.1
0.5
1
2.5
5
10
20
–
1,000 10,000
log [BEZ235] (nM)
1 10 100 1,000 10,000
1,200
1,000
800
600
400
200
0
Figure 9 | Validation of the two-step therapy in colorectal cancer cell lines. (a) BEZ235 dose–response curve of DLD-1 parental (Ras and PI3K active)
versus DLD-1 WT (Ras active, PI3K wild type) cell lines. (b) Time course of mTORC1 activation by bortezomib in DLD-1 cells. Each data point represents
the average of two to three western blottings. (c) mTORC1 activation status in response to bortezomib 12 h after treatment. (d) BEZ235 dose –response
curve of DLD-1 cells after pretreatment with dimethyl sulfoxide (DMSO; control) or indicated doses of bortezomib for 24 h. (e) Growth rates of DLD-1
xenografts treated with indicated compounds. Data points are normalized to tumour size at the beginning of drug treatment (day 9). (f) Percent change in
DLD-1 xenograft tumour volumes at the last day of treatment (day 31; Po0.05, Mann–Whitney test). Error bars: s.e.m. 10 animals. Uncropped gels used to
generate c can be found in Supplementary Fig. 8g.
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/ncomms13615
12 NATURE COMMUNICATIONS | 7:13615 | DOI: 10.1038/ncomms13615 | www.nature.com/naturecommunications
cells—induced dependence—suggests that combinatorial therapy
or the use of less selective compounds is a useful approach against
at least some genetically complex tumours.
Methods
Tumour genome analysis. Mutation proﬁles of 212 TCGA colorectal
tumours—for which whole-exome sequencing and copy number alteration data are
available—were analysed using cBioPortal62,63. Genomic analysis was focused on
25 genes previously identiﬁed by TCGA as recurrently mutated genes in colorectal
cancer.
Fly strains and multigenic models. Fly lines used in this study are (chromosome
locations and sources in parentheses): UAS-rasG12V (second, G. Halder), UAS-p53Ri
(second, VDRC), UAS-ptenRi (third, VDRC), UAS-apcRi (second and third,
VDRC), UAS-dSmad4Ri (second and third, VDRC), UAS-tsc1Ri (second, TRIP),
UAS-tsc2Ri (second, VDRC) and UAS-raptorRi (second, TRIP), UAS-dcr2
(X, Bloomington), UAS-GFP (third, Bloomington), byn-gal4 (third, V. Hartenstein)
and tub-gal80ts (third, Bloomington). Double, triple and quadruple models
were generated by making the following double recombinant chromosomes and
combining them with each other or individual transgenes using standard genetic
crosses; of note, the complexity of the multi-transgene lines prevented backcrossing
and we cannot exclude effects from differing genetic backgrounds. On the second
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chromosome: UAS-rasG12V UAS-p53Ri, UAS-rasG12V UAS-apcRi and UAS-p53Ri
UAS-apcRi. On the third chromosome: UAS-dSmad4Ri UAS-apcRi, UAS-dSmad4Ri
UAS-ptenRi and UAS-ptenRi UAS-apcRi. For the quintuple, a triple recombinant
second chromosome containing UAS-rasG12V, UAS-p53Riand UAS-apcRi was
generated and combined with the third chromosome containing UAS-dSmad4Ri
and UAS-ptenRitransgenes. All models contain the same second chromosome
insertions of UAS-rasG12V and UAS-p53Ri, and third chromosome insertions of
UAS-apcRi, UAS-dSmad4Ri and UAS-ptenRiwith the following exceptions: the
quintuple rasG12V p53Ri dSmad4Ri ptenRi apcRi, the quadruple rasG12V apcRi
dSmad4Ri ptenRi and the triple apcRi dSmad4Ri ptenRi carry a second chromosome
insertion of UAS-apcRi.
Targeted expression in the adult hindgut. Multigenic combinations were
targeted to the adult hindgut using the hindgut-speciﬁc GAL4 driver line byn-gal4
(V. Hartenstein) plus tub-gal80ts (Bloomington). Adult females used in this study
were generated by crossing ﬂies carrying these multigenic combinations to
UAS-dcr2; þ ; byn-gal4 UAS-GFP tub-gal80ts/S-T. Crosses were kept at 16 C, to
keep the transgenes silent during development, and adult females were transferred
to 29 C, to induce transgene expression. In addition, GFP and Dcr2 (Dicer2)
were co-expressed to mark the hindgut cells and to facilitate RNAi-mediated
knockdown, respectively.
Compound feeding. Compounds used in this study were (stock concentrations
and sources in parentheses) selumetinib (200mM, Selleck Chemicals), SL327
(200mM, Tocris), GW5074 (100mM, Tocris), sorafenib (200mM, LC Labs),
LY294002 (200mM, LC Labs), rapamycin (200mM, LC Labs), BEZ235 (20mM,
LC Labs), dasatinib (200mM, LC Labs), SP600125 (200mM, LC Labs), bortezomib
(200mM, LC Labs), cisplatin (200mM, Sigma), panobinostat (200mM, LC Labs),
wortmannin (200mM, LC Labs), PI-103-HCl (100mM, Tocris), everolimus
(100mM, LC Labs), enzastaurin (50mM, LC Labs) and SC79 (200mM, Tocris).
Compound-treated food was made by diluting compound stocks in semi-
deﬁned Drosophila medium to 0.5% dimethyl sulfoxide. Adult ﬂies were provided
with fresh compound/food every other day. Animals were randomized before drug
treatment and scored blindly. Animals that were dead at the time of scoring were
excluded. Food intake was quantiﬁed 4 days after induction for a period of 8 h
using the CAFE´ assay as previously described64,65.
Statistical analysis of the dissemination assay. Sample sizes and phenotypic
categories for the dissemination phenotype were determined empirically to
generate a robust and reproducible quantitative readout. Animals that were dead at
the time of scoring were excluded. Statistical signiﬁcance for the dissemination
assay was calculated using Fisher’s exact test, to allow the analysis of contingency
tables where sample sizes are relatively small. Use of a 4 2 contingency table
allowed pairwise comparisons of the dissemination phenotype, which has four
phenotypic categories, between different genotypes and/or treatment conditions.
Each experiment was performed in duplicate (n¼ 25–30 for each replicate) and
multiple times. Error bars indicate s.e.m. Experiments that show a high degree of
variance between biological replicates were considered inconclusive and repeated.
Immunohistochemistry. Hindguts dissected in ice-cold PBS were ﬁxed with 4%
paraformaldehyde, 0.3% Triton X in PBS for 15min, rinsed 3 in PBS, washed
15min in PBS, blocked 1 h in 0.1% Triton X, 1% normal goat serum in PBS,
incubated with primary antibody at 4 C overnight, rinsed three times in PBS,
blocked for 1 h and incubated in secondary antibody for 2 h at room temperature.
Hindguts were mounted in Vectashield with 4,6-diamidino-2-phenylindole (Vector
Laboratories). Primary and secondary antibodies were diluted in block solution.
Primary antibodies were as follows: rabbit anti-Laminin (1:500, Abcam,
catalogue number ab47651), mouse anti-MMP1 (1:100, DSHB, catalogue number
3B8D12-s), rabbit anti-Src-pY418 (1:100, Invitrogen, catalogue number 44660G),
mouse anti-BrDU (1:10, BD Biosciences, catalogue number 347580), rabbit
anti-APC (1:1,000, gift from Y. Ahmed51) and rabbit anti-cleaved Caspase 3 (1:100,
Cell Signaling, catalogue number 9661S). Alexa-568- or 633-conjugated goat
anti-mouse and anti-rabbit antibodies were used as secondary antibodies (1:1,000,
Invitrogen catalogue number A-11036, A-11004, A-21126 and A-21071). Muscle
labelling was performed with Alexa-568-conjugated phalloidin (1:200, Invitrogen,
catalogue number A-12380). SA-b-gal staining was performed using a kit from Cell
Signaling (catalogue number 9860).
BrDU incorporation assay. To label proliferating cells, adults were fed fed
5mgml 1 BrDU in semi-deﬁned Drosophila medium daily for 7 days. Dissected
guts were processed for antibody staining as described above with the addition of
an initial DNAse treatment step (200Uml 1) at 37 C for 1 h.
Imaging and scoring. Fluorescence images were visualized on a Leica TCS SPE
confocal microscope and processed using Leica LAS-AF software. Scoring and
imaging of SA-b-gal staining was performed using an Olympus BX41 microscope
and a Nikon DS-Ri1 camera. Dissemination was imaged and scored using a Leica
MZ16F dissecting scope with a GFP ﬁlter under  10 magniﬁcation.
Western blot analysis. Lysates for western blot analysis were made by grinding ten
hindguts in lysis buffer (50mM Tris-HCl, 150mM NaCl, 1mM EDTA and 1% NP-
40) supplemented with protease and phosphatase inhibitor cocktails (Sigma). Lysates
were boiled for 10min in SDS sample buffer and reducing agent, resolved on SDS–
PAGE and transferred using standard protocols. Protein concentrations were deter-
mined using BioRad Protein Assay Dye Reagent. For signal detection, Immobilon
Chemiluminescent horseradish peroxidase Substrate (Millipore) was used. After
blocking, membranes were cut into horizontal strips and probed with appropriate
antibodies; membranes were reassembled before developing. Bands were quantiﬁed
using Gel Analyzer. Uncropped gels used to assemble the panels shown in all ﬁgures
along with molecular markers are shown in Supplementary Fig. 8.
Primary antibodies were as follows: rabbit anti Drosophila phospho-AKT
(p-Ser505; Drosophila equivalent of mammalian AKT p-Ser473, 1:1,000, Cell
Signaling, catalogue number 4054S), rabbit anti-mouse AKT (1:1,000, Cell Signaling,
catalogue number 4691S), rabbit anti-mouse phospho-4EBP (Thr37/46, 1:1,000, Cell
Signaling, catalogue number 2855S), rabbit anti-human phospho-AKT (Ser473,
1:1,000, Cell Signaling, catalogue number 4060S), mouse anti-chicken
a-actin (1:1,000, DSHB catalogue number JLA20-s), rabbit anti-GFP (1:2,000, Sigma,
catalogue number G1544), rabbit anti Drosophila P53 (1:1,000, DSHB, catalogue
number H3), rabbit anti Drosophila Pten (1:1,000, gift from A. Wodarz52), mouse
anti-dpERK (Thr183/Tyr185, 1:2,000, Sigma, catalogue number M8159), rabbit anti
human phospho-S6 (Ser 235/236, 1:1,000, Cell Signaling, catalogue number 2211)
and mouse anti Drosophila Syntaxin (1:1,000, DSHB, catalogue number 8C3).
Horseradish peroxidase-conjugated anti-mouse and anti-rabbit secondary antibodies
were used (1:5,000, Cell Signaling, catalogue number 7074, 7076).
Cell culture. Parental DLD-1 and HCT-116 cell lines (ATCC) and their PI3K
wild-type derivatives (DLD-1 WT and HCT116 WT)58 from Dr. Bert Vogelstein’s
laboratory were maintained using DMEM medium with 10% fetal bovine serum
(FBS). As previously reported58, PI3K pathway activity was sensitive to serum level
and batch; all experiments were done under low serum conditions (2.5% FBS,
CellGro, Lot number K043-6HI).
MTT assay. Cells were grown in sterile 25 cm2 ﬂasks to 80% conﬂuence,
trypsinized, re-suspended in 100ml DMEM with 2.5% FBS and seeded in 96-well
plates in equal numbers. After 24 h, cells were treated with compounds diluted in
DMEM with 2.5% FBS as indicated. MTT (3-(4,5-dimethylthiazol-2-yl)-2,
5-diphenyltetrazolium bromide) assay was performed by replacing medium with
fresh DMEM plus 2.5% FBS and 10mgml 1 MTT reagent (Fisher Scientiﬁc) in
PBS at a ratio of 5:1 (120 ml per well; 96-well plates). Cells were incubated at 37 C
for 3 h, media removed and cells incubated in MTT solvent (4mM HCl, 0.1% NP40
in isopropanol) on a shaker. MTT formazan levels were determined spectro-
photometrically. Each experiment was done in quadruplicate and relative viability
expressed as fold change in adjusted absorbance compared with untreated and
dimethyl sulfoxide-treated controls in each plate. Cell lines were checked for
mycoplasma contamination before use.
Xenograft study. Xenograft experiments were carried out by Gregory Carbonetti
and Dr. Elisa de Stanchina at the Antitumor Assessment Core Facility, Memorial
Sloan-Kettering Cancer Center in compliance with institutional guidelines under
an institutional animal care and use committee (IACUC)-approved protocol. Nu/
nu athymic females were injected with ten million cells subcutaneously (single
ﬂank) with matrigel. Drug treatment was initiated when tumours reached
B80–100mm3 using the following schedule: Monday: bortezomib (intraper-
itoneal) or vehicle; Tuesday–Friday: BEZ235 (per os, 40mg kg 1 per day);
Saturday and Sunday: off for 3 weeks. Tumour growth was measured twice per
week. Statistical signiﬁcance was determined using Mann–Whitney test (Po0.05).
6–8 weeks old mice were used in experiments.
Colon sphere cultures and allograft experiments. Adenomas from APC/KRAS/
PTEN mouse tumours were cultured in vitro as described66. Spheres were cultured
for 3 days and treated with indicated doses of bortezomib, SC79 and BEZ235. Cell
viability was quantiﬁed using CellTiter-Blue cell viability assay (Promega) following
the manufacturer’s protocol. Drug treatment was done without epidermal growth
factor. For allograft experiments, ﬁve spheres were injected subcutaneously into
each mouse (CD1 nude mice), tumours were established for 10 days before
treatment: Monday: bortezomib (intraperitneal) or vehicle; Tuesday–Friday:
BEZ235 (per os, 45mg kg 1 per day); Saturday and Sunday: off for 3 weeks.
Tumour growth was measured every 3 days. All animal work was carried
out in line with the UK Animal Scientiﬁc Procedures Act 1986 and the EU
Directive 2010.
Data availability. The authors declare that the data supporting the ﬁndings of
this study are available within the paper and its Supplementary Information
ﬁles, public databases as indicated, or from the author upon request. TGCA
colorectal cancer dataset used in this study is publicly available in cbioportal
(www.cbioportal.org; study: TCGA, Nature 2012; case/patient set: 212 tumours
with sequencing and CNA data).
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